Claims for Patent: 6,846,662

Summary for Patent: 6,846,662

Title:	Vertebrate telomerase genes and proteins and uses thereof
Abstract:	Nucleic acid molecules encoding vertebrate telomerase are provided. Gene products, expression vectors and host cells suitable for expressing telomerase are also provided. Methods for identifying inhibitors of telomerase activity and inhibitor compositions are disclosed.
Inventor(s):	Kilian; Andrzej (Canberra, AU), Bowtell; David (Coburg, AU)
Assignee:	The Monticello Group Ltd. (Seattle, WA)
Application Number:	09/502,498
Patent Claims:	1. An isolated protein, wherein the protein comprises one of SEQ ID Nos. 37, 39, 42, 44, 46, 48, 50, 56-58, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86. 2. A fragment of the protein according to claim 1, wherein the fragment consists of SEQ ID Nos: 24, 26, 28, or 31. 3. An isolated protein comprising SEQ ID No: 46 or a variant thereof, wherein the variant has at least 90% amino acid sequence identity and wherein the variant binds telomerase RNA (hTR), and wherein the variant is not SEQ ID No: 2. 4. An isolated protein comprising a variant of SEQ ID Nos. 35, 37, 39, 42, 44, 46, 48, 50, 56-58, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84, 85 or 86, wherein the variant has at least 90% amino acid identity with said sequences, and wherein the variant binds telomerase RNA (hTR) or exhibits telomerase activity, and wherein the variant is not SEQ ID No: 2. 5. An isolated protein consisting of a fragment of SEQ ID No: 44, wherein the fragment comprises amino acids 530 through 1096, 824 through 1096, or 911 through 1096. 6. An isolated protein encoded by an isolated nucleic acid molecule encoding a splice variant of a gene sequence capable of being spliced to encode a reference human telomerase of SEQ ID No: 2, wherein the splice variant has at least one of the following insertions or deletions; (a) an insertion of alternative intron/exon X comprising SEQ ID No: 32 at its 5'-end following nucleotide 1766 of SEQ ID No: 1; (b) an insertion of nucleic acid sequence encoding alternative intron/exon 1 (SEQ ID NO: 24) following nucleotide 1950 of SEQ ID No: 1; (c) a deletion of nucleotides 2131 through 2166 of SEQ ID No: 1; (d) a deletion of nucleotides 2287 through 2468 of SEQ ID No: 1; (e) an insertion of alternative intron/exon 2 comprising SEQ ID No: 29 at its 5' end following nucleotide 2843 of SEQ ID No: 1; and (f) an insertion of nucleic acid sequence encoding alternative intron/exon 3 (SEQ ID No: 31) at nucleotide 3157 of SEQ ID No: 1. and wherein the splice variant does not encode SEQ ID No: 2. 7. An isolated protein consisting of SEQ ID NO: 35.

Details for Patent 6,846,662

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-07-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-07-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-07-01